Novel Approaches in the Treatment of Dyslipidaemia and T2DM
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
Related MIMS Drugs